• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

土霉素对溶血曼氏杆菌和多杀性巴氏杆菌体外效力检测的标准化方法与非标准化方法比较

Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida.

作者信息

Lees P, Illambas J, Pelligand L, Toutain P-L

机构信息

Royal Veterinary College, Hawkshead Campus, Hatfield, Hertfordshire AL9 7TA, United Kingdom.

Toxalim, Université de Toulouse, INRA, ENVT, 23, Chemin des Capelles-BP 87614, 31076 Toulouse, France.

出版信息

Vet J. 2016 Dec;218:60-64. doi: 10.1016/j.tvjl.2016.11.006. Epub 2016 Nov 17.

DOI:10.1016/j.tvjl.2016.11.006
PMID:27938710
Abstract

The in vitro pharmacodynamics of oxytetracycline was established for six isolates of each of the calf pneumonia pathogens Mannheimia haemolytica and Pasteurella multocida. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC) and bacterial time-kill curves were determined in two matrices, Mueller Hinton broth (MHB) and calf serum. Geometric mean MIC ratios, serum:MHB, were 25.2:1 (M. haemolytica) and 27.4:1 (P. multocida). The degree of binding of oxytetracycline to serum protein was 52.4%. Differences between serum and broth MICs could not be accounted for by oxytetracycline binding to serum protein. In vitro time-kill data suggested a co-dependent killing action of oxytetracycline. The in vitro data indicate inhibition of the killing action of oxytetracycline by serum factor(s). The nature of the inhibition requires further study. The outcome of treatment with oxytetracycline of respiratory tract infections in calves caused by M. haemolytica and P. multocida may not be related solely to a direct killing action.

摘要

对溶血性曼氏杆菌和多杀性巴氏杆菌这两种犊牛肺炎病原体的六个分离株,分别测定了土霉素的体外药效学指标。在两种基质中测定了最低抑菌浓度(MIC)、最低杀菌浓度(MBC)以及细菌时间-杀菌曲线,这两种基质分别是 Mueller Hinton 肉汤(MHB)和犊牛血清。血清与 MHB 的几何平均 MIC 比值分别为 25.2:1(溶血性曼氏杆菌)和 27.4:1(多杀性巴氏杆菌)。土霉素与血清蛋白的结合程度为 52.4%。血清和肉汤 MIC 之间的差异不能用土霉素与血清蛋白的结合来解释。体外时间-杀菌数据表明土霉素存在协同依赖性杀菌作用。体外数据表明血清因子会抑制土霉素的杀菌作用。这种抑制作用的性质需要进一步研究。土霉素治疗由溶血性曼氏杆菌和多杀性巴氏杆菌引起的犊牛呼吸道感染的效果可能不仅仅与直接杀菌作用有关。

相似文献

1
Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida.土霉素对溶血曼氏杆菌和多杀性巴氏杆菌体外效力检测的标准化方法与非标准化方法比较
Vet J. 2016 Dec;218:60-64. doi: 10.1016/j.tvjl.2016.11.006. Epub 2016 Nov 17.
2
Pharmacodynamics of marbofloxacin for calf pneumonia pathogens.马波沙星对犊牛肺炎病原菌的药效学研究。
Res Vet Sci. 2013 Jun;94(3):675-81. doi: 10.1016/j.rvsc.2012.12.012. Epub 2013 Jan 31.
3
Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.土霉素对犊牛病原菌溶血曼氏杆菌和多杀性巴氏杆菌的药代动力学-药效学整合与建模
J Vet Pharmacol Ther. 2018 Feb;41(1):28-38. doi: 10.1111/jvp.12439. Epub 2017 Jul 23.
4
Pharmacokinetic and pharmacodynamic integration and modelling of marbofloxacin in calves for Mannheimia haemolytica and Pasteurella multocida.对用于治疗溶血曼氏杆菌和多杀巴斯德氏菌的马波沙星在犊牛体内的药代动力学和药效学整合与建模。
Vet J. 2013 Jan;195(1):53-8. doi: 10.1016/j.tvjl.2012.08.027. Epub 2012 Oct 16.
5
Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media.三种生长培养基中小牛病原菌溶血曼氏杆菌和多杀巴斯德氏菌对四环素、土霉素和强力霉素的敏感性差异
J Vet Pharmacol Ther. 2019 Jan;42(1):52-59. doi: 10.1111/jvp.12719. Epub 2018 Sep 28.
6
Pharmacodynamics of florfenicol for calf pneumonia pathogens.氟苯尼考治疗犊牛肺炎病原菌的药效学研究。
Vet Rec. 2013 Mar 30;172(13):340. doi: 10.1136/vr.101155. Epub 2013 Mar 12.
7
Pharmacokinetic/pharmacodynamic integration and modelling of amoxicillin for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.阿莫西林对犊牛病原菌溶血曼氏杆菌和多杀性巴氏杆菌的药代动力学/药效学整合及建模
J Vet Pharmacol Ther. 2015 Oct;38(5):457-70. doi: 10.1111/jvp.12207. Epub 2015 Feb 9.
8
A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida.血清对泰拉霉素体外抗溶血曼氏杆菌和多杀性巴氏杆菌效力具有显著的增强作用。
J Vet Pharmacol Ther. 2017 Oct;40(5):419-428. doi: 10.1111/jvp.12372. Epub 2016 Nov 27.
9
Treatment history and antimicrobial susceptibility results for Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni isolates from bovine respiratory disease cases submitted to the Iowa State University Veterinary Diagnostic Laboratory from 2013 to 2015.2013年至2015年提交至爱荷华州立大学兽医诊断实验室的牛呼吸道疾病病例中,溶血曼氏杆菌、多杀巴斯德氏菌和睡眠嗜组织菌分离株的治疗史及药敏结果。
J Vet Diagn Invest. 2018 Jan;30(1):99-104. doi: 10.1177/1040638717737589. Epub 2017 Oct 15.
10
A ten-year (2000-2009) study of antimicrobial susceptibility of bacteria that cause bovine respiratory disease complex--Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni--in the United States and Canada.一项为期十年(2000年至2009年)的关于引起牛呼吸道疾病综合征的细菌——溶血曼氏杆菌、多杀性巴氏杆菌和睡眠嗜组织菌——在美国和加拿大的抗菌药敏性研究。
J Vet Diagn Invest. 2012 Sep;24(5):932-44. doi: 10.1177/1040638712457559.

引用本文的文献

1
Determination of pharmacokinetic-pharmacodynamic cutoff values of oxytetracycline in calves and adult cattle using population pharmacokinetic modeling.使用群体药代动力学模型确定犊牛和成年牛中土霉素的药代动力学-药效学截止值。
Front Microbiol. 2024 Dec 4;15:1498219. doi: 10.3389/fmicb.2024.1498219. eCollection 2024.
2
En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.迈向兽医抗菌药物敏感性试验欧洲临床断点:解释VetCAST方法的立场文件。
Front Microbiol. 2017 Dec 15;8:2344. doi: 10.3389/fmicb.2017.02344. eCollection 2017.
3
Pharmacokinetic/pharmacodynamic integration and modelling of oxytetracycline for the porcine pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
土霉素对猪肺炎病原体胸膜肺炎放线杆菌和多杀性巴氏杆菌的药代动力学/药效学整合与建模
J Vet Pharmacol Ther. 2017 Oct;40(5):505-516. doi: 10.1111/jvp.12385. Epub 2017 Jan 16.